Health care industry
Amazon launches GLP-1 weight loss program, promising ‘fast, convenient’ access
Amazon GLP-1 treatment Source: Amazon Inc. Amazon is pushing deeper into the booming weight loss market, unveiling Tuesday a new program that aims to simplify access to popular GLP-1 treatments. The company said its primary care arm, Amazon One Medical, is launching a GLP-1 management program that integrates obesity treatment into routine care. The offering […]
Read More
UnitedHealth tops quarterly estimates, hikes profit outlook as insurer manages high medical costs
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Tuesday posted first-quarter earnings that topped estimates and hiked its 2026 profit outlook, as the company better manages high medical costs and streamlines its operations. The nation’s largest private insurer said it expects […]
Read More
Jim Cramer warns against chasing ‘parabolic’ stocks and says there’s opportunity in overlooked names instead
Key Points CNBC’s Jim Cramer cautioned against chasing “parabolic” tech and AI stocks, warning those trades can quickly reverse. He emphasized the importance of finding opportunities in overlooked names and the need for diversification. CNBC’s Jim Cramer said Monday he’s wary of investors piling into the market’s hottest trades, arguing that chasing “parabolic” moves often […]
Read More
How Trump’s psychedelics executive order could unlock stalled cannabis reform
Advocates attend a news conference about the “impact of incarcerating those charged with marijuana-related offenses,” and policy reform ideas, outside the U.S. Capitol on April 20, 2026. Tom Williams | CQ-Roll Call, Inc. | Getty Images A White House executive order on psychedelics, signed by President Donald Trump on Saturday, aims to speed up research […]
Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]
Read More
Naomi Watts wants women to own their menopause journey: ‘Why is it so taboo when we are half the population?’
Stripes Beauty Founder and Chief Creative Officer Naomi Watts speaking at the CNBC Changemakers Summit in New York City on April 16, 2026. CNBC Oscar-nominated actress Naomi Watts has continued to have fame on the screen into her 50s, but she is building more of her life story around navigating deeply personal and often unspoken […]
Read More
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz. U.S. Department of Health and Human Services President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency. Schwartz will have to be confirmed by the Senate, […]
Read More
Here’s our monthly update on all 31 portfolio stocks, including 3 on the buy list
The CNBC Investing Club held its April Monthly Meeting on Thursday, with Jim Cramer and Jeff Marks, director of portfolio analysis, hashing it out on each stock in the portfolio. The confab came a day after the S & P 500 closed at its first record high since late January, punctuating its dramatic comeback from […]
Read More
RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Piotr Swat | Lightrocket | Getty Images As its high-margin compounded GLP-1 business evolves, Hims & Hers Health may be finding a new opportunity in peptides. Shares of the telehealth company jumped Thursday after HHS Secretary Robert F. Kennedy Jr. announced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to […]
Read More
J&J tops first-quarter profit estimates even as Stelara sales plunge
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. And the company expressed confidence in its just-approved once-daily, oral psoriasis treatment, Icotyde, saying about 1,500 […]
Read More